<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">636760</article-id><article-id pub-id-type="doi">10.26442/20751753.2024.8.202860</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Pityriasis rubra pilaris: A review</article-title><trans-title-group xml:lang="ru"><trans-title>Красный волосяной лишай</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Adaskevich</surname><given-names>Vladimir P.</given-names></name><name xml:lang="ru"><surname>Адаскевич</surname><given-names>Владимир Петрович</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф., зав. каф. дерматовенерологии и косметологии</p></bio><email>vitebsk.derma@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Vitebsk State Medical University</institution></aff><aff><institution xml:lang="ru">УО «Витебский государственный ордена Дружбы народов медицинский университет»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-10-06" publication-format="electronic"><day>06</day><month>10</month><year>2024</year></pub-date><volume>26</volume><issue>8</issue><issue-title xml:lang="en">Dermatology and allergology</issue-title><issue-title xml:lang="ru">Дерматология и аллергология</issue-title><fpage>485</fpage><lpage>491</lpage><history><date date-type="received" iso-8601-date="2024-10-06"><day>06</day><month>10</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-10-06"><day>06</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/636760">https://consilium.orscience.ru/2075-1753/article/view/636760</self-uri><abstract xml:lang="en"><p><italic>Pityriasis rubra pilaris</italic> (PRP, syn.: Devergie's disease) is a rare idiopathic papulo-squamous inflammatory skin disease characterized by follicular papules, palmar-plantar keratoderma, scaling plaques of orange-red color with characteristic foci of unaffected skin. Histologically, the alternating pattern of orthokeratosis and parakeratosis is considered a distinctive feature of PRP (staggered hyperkeratosis). A violation of the regulation of innate immunity is a component of the pathogenesis of PRP. Congenital mutations of CARD 14 or concomitant antigens, which can take the form of iatrogenic lesions, infections or malignant neoplasms, can be the initial triggers of the disease, although the etiology is often idiopathic. There are classically five subtypes of the disease, depending on the age of onset and clinical picture. Type VI PRP is associated with infection caused by the human immunodeficiency virus. CARD 14-associated papulosquamous rash and discoid dermatitis of the face represent new clinical phenotypes of PRP. Devergie's disease has a pronounced negative impact on the quality of life, and those who become ill are at increased risk of depression and suicide. Ixekizumab, methotrexate and secukinumab can be considered as systemic drugs of the first choice. If there is a contraindication to immunosuppressive therapy, high doses of isotretinoin are recommended. Topical agents, including calcipotriene, calcineurin inhibitors, emollients and topical corticosteroids, are used as additional therapy.</p></abstract><trans-abstract xml:lang="ru"><p>Красный волосяной лишай (КВЛ, син.: болезнь Девержи, красный волосяной отрубевидный лишай, питириаз красный волосяной отрубевидный,<italic> pityriasis rubra pilaris</italic>) – редкое идиопатическое папулезно-сквамозное воспалительное заболевание кожи, характеризующееся фолликулярными роговыми папулами, ладонно-подошвенной кератодермией, шелушащимися бляшками оранжево-красного цвета с характерными очагами непораженной кожи. Гистологически чередующийся паттерн орто- и паракератоза считается отличительной чертой КВЛ (шахматный гиперкератоз). Нарушение регуляции врожденного иммунитета является компонентом патогенеза КВЛ. Врожденные мутации гена CARD14 или сопутствующие антигены, которые могут принимать форму ятрогенных поражений, инфекций или злокачественных новообразований, могут быть начальными пусковыми механизмами заболевания, хотя этиология часто идиопатическая. Классически подразделяют 5 подтипов заболевания в зависимости от возраста начала и клинической картины. КВЛ VI типа ассоциирован с инфекцией, вызванной вирусом иммунодефицита человека. CARD14-ассоциированная папулезно-сквамозная сыпь и дискоидный дерматит лица представляют собой новые клинические фенотипы КВЛ. Последний оказывает выраженное негативное влияние на качество жизни, а заболевшие подвержены повышенному риску депрессии и суициду. Иксекизумаб, метотрексат и секукинумаб могут рассматриваться как системные препараты 1-го выбора. При наличии противопоказания к иммуносупрессивной терапи рекомендуется прием высоких доз изотретиноина. В качестве дополнительной терапии применяются местные средства, включая кальципотриен, ингибиторы кальциневрина, смягчающие средства и топические кортикостероиды.</p></trans-abstract><kwd-group xml:lang="en"><kwd>pityriasis rubra pilaris</kwd><kwd>Devergie disease</kwd><kwd>pathogenesis</kwd><kwd>clinic</kwd><kwd>diagnosis</kwd><kwd>therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>красный волосяной отрубевидный лишай</kwd><kwd>болезнь Девержи</kwd><kwd>патогенез</kwd><kwd>клиника</kwd><kwd>диагностика</kwd><kwd>терапия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Joshi TP, Duvic M. Pityriasis rubra pilaris: An updated review of clinical presentation, etiopathogenesis, and treatment options. Am J Clin Dermatol. 2024;25(2):243-59. DOI:10.1007/s40257-023-00836-x</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Greiling TM, Brown F, Syed HA. Pityriasis rubra pilaris. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2024.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Brown F, Badri T. Pityriasis rubra pilaris. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK482436. Accessed: 23.05.2024.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Zhou T, Al Muqrin A, Abu-Hilal M. Updates on pityriasis rubra pilaris: A scoping review. J Cutan Med Surg. 2024;28(2):158-66. DOI:10.1177/12034754231223159</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Bertin J, Wang L, Guo Y, et al. CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B. J Biol Chem. 2001;276(15):11877-82. DOI:10.1074/jbc.M010512200</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Scudiero I, Zotti T, Ferravante A, et al. Alternative splicing of CARMA2/CARD14 transcripts generates protein variants with differential effect on NF-κB activation and endoplasmic reticulum stress-induced cell death. J Cell Physiol. 2011;226(12):3121-31. DOI:10.1002/jcp.22667</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Craiglow BG, Boyden LM, Hu R, et al. CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris. J Am Acad Dermatol. 2018;79(3):487-94. DOI:10.1016/j.jaad.2018.02.034</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Silva JA, de Carvalho Mesquita K, Igreja AC, et al. Paraneoplastic cutaneous manifestations: concepts and updates. An Bras Dermatol. 2013;88(1):9-22. DOI:10.1590/s0365-05962013000100001</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol. 1980;5:105-12. DOI:10.1111/j.1365-2230.1980.tb01676.x</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Ross NA, Chung HJ, Li Q, et al. Epidemiologic, clinicopathologic, diagnostic, and management challenges of pityriasis rubra pilaris: A case series of 100 patients. JAMA Dermatol. 2016;152(6):670-5. DOI:10.1001/jamadermatol.2016.0091</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Ji-Xu A, Lei DK, Maloney NJ, Worswick S. Clinical course, diagnostic patterns, and treatment outcomes in patients with pityriasis rubra pilaris. J Am Acad Dermatol. 2022;87(6):1450-1. DOI:10.1016/j.jaad.2022.07.039</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ghatnekar S, Shah N, Min MS, et al. Clinical features and eosinophilia in pityriasis rubra pilaris: A multicenter cohort. J Am Acad Dermatol. 2022;86:907-9. DOI:10.1016/j.jaad.2021.03.043</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Yang CC, Shih IH, Lin WL, et al. Juvenile pityriasis rubra pilaris: Report of 28 cases in Taiwan. J Am Acad Dermatol. 2008;59(6):943-8. DOI:10.1016/j.jaad.2008.07.054</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Allison DS, El-Azhary RA, Calobrisi SD, Dicken CH. Pityriasis rubra pilaris in children. J Am Acad Dermatol. 2002;47(3):386-9. DOI:10.1067/mjd.2002.124619</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Blauvelt A, Nahass GT, Pardo RJ, Kerdel FA. Pityriasis rubra pilaris and HIV infection. J Am Acad Dermatol. 1991;24 24(5 Pt 1):703-5. DOI:10.1016/0190-9622(91)70106-c</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Miralles ES, Núñez M, De Las Heras ME, et al. Pityriasis rubra pilaris and human immunodefciency virus infection. Br J Dermatol. 1995; 133(6):990-3. DOI:10.1111/j.1365-2133.1995.tb06939.x</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Nair PA, Sheth N. Atypical adult-onset pityriasis rubra pilaris in an HIV-positive adult male. Indian J Dermatol. 2018;63(6):522-4. DOI:10.4103/ijd.IJD_141_18</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Kranyak A, Shuler M. Pityriasis rubra pilaris rapidly cleared with Ixekizumab in an HIV-positive patient. JAAD Case Rep. 2022;27:55-7. DOI:10.1016/j.jdcr.2022.07.015</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Williams A, George A, Thomas EA, Koshy JM. Pityriasis rubra pilaris type 6: A case report in an AIDS patient. Indian J Sex Transm Dis AIDS. 2020;41(1):100-1. DOI:10.4103/ijstd.IJSTD_120_15</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Allegue F, Fachal C, Iglesias B, Zulaica A. Facial discoid dermatosis: a new variant of pityriasis rubra pilaris? Actas Dermosifiliogr. 2022;113(7):728-31. DOI:10.1016/j.ad.2021.01.006</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Li N, Tao J, Zhang J, et al. A novel mutation in a CARD14-associated papulosquamous eruption. Pediatr Dermatol. 2023;40(4):706-9. DOI:10.1111/pde.15254</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Takeichi T, Terawaki S, Kubota Y, et al. A patient with CARD14-associated papulosquamous eruptions showing atopic dermatitis-like features. J Eur Acad Dermatol Venereol. 2021;35(1):e58-9. DOI:10.1111/jdv.16799</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Ko CJ, Heald P, Antaya RJ, Bolognia JL. Facial discoid dermatosis. Int J Dermatol. 2010;49(2):189-92. DOI:10.1111/j.1365-4632.2009.04206.x</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Salman A, Tekin B, Berenjian A, et al. Facial discoid dermatosis: A further case of a novel entity. J Dermatol. 2015;42(11):1132-3. DOI:10.1111/1346-8138.13045</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Gan EY, Ng SK, Goh CL, Lee SSJ. Recalcitrant psoriasiform dermatosis of the face: is it related to pityriasis rubra pilaris? J Cutan Pathol. 2018;45(7):491-7. DOI:10.1111/cup.13148</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Rypka KJ, Fulk TS, Afsaneh A, et al. Improvement of facial discoid dermatosis with ustekinumab treatment. JAMA Dermatol. 2022;158(9):1079-80. DOI:10.1001/jamadermatol.2022.2478</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Davis AE, Raine BE, Swartzman I, et al. Rethinking pityriasis rubra pilaris as a paraneoplastic syndrome: two cases of pityriasis rubra pilaris with concomitant underlying malignancy. JAAD Case Rep. 2023;32:90-5. DOI:10.1016/j.jdcr.2022.12.007</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Roenneberg S, Biedermann T. Pityriasis rubra pilaris: algorithms for diagnosis and treatment. J Eur Acad Dermatol Venereol. 2018;32(6):889-98. DOI:10.1111/jdv.14761</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Naidoo A, Sibbald C, Fleming PJ, Piguet V. Use of biologics in pityriasis rubra pilaris refractory to first-line systemic therapy: A systematic review. J Cutan Med Surg. 2020;24(1):73-8. DOI:10.1177/1203475419887731</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Kromer C, Sabat R, Celis D, Mössner R. Systemic therapies of pityriasis rubra pilaris: A systematic review. J Dtsch Dermatol Ges. 2019;17(3):243-59. DOI:10.1111/ddg.13718</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Wassef C, Lombardi A, Rao BK. Adalimumab for the treatment of pityriasis rubra pilaris: A case report. Cutis. 2012;90(5):244-7.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Wohlrab J, Kreft B. Treatment of pityriasis rubra pilaris with ustekinumab. Br J Dermatol 2010;163(3):655-6. DOI:10.1111/j.1365-2133.2010.09855.x</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Napolitano M, Lembo L, Fania L, et al. Ustekinumab treatment of pityriasis rubra pilaris: A report of five cases. J Dermatol. 2018;45(2):202-6. DOI:10.1111/1346-8138.14114</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Haynes D, Strunck JL, Topham CA, et al. Evaluation of ixekizumab treatment for patients with pityriasis rubra pilaris: A single-arm trial. JAMA Dermatol. 2020;156(6):668-75. DOI:10.1001/jamadermatol.2020.0932</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Boudreaux BW, Pincelli TP, Bhullar PK, et al. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: A single-arm clinical trial with transcriptomic analysis. Br J Dermatol. 2022;187(5):650-8. DOI:10.1111/bjd.21708</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Ji-Xu A, Lei DK, Worswick S, et al. Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris. Br J Dermatol. 2022;187(6):1024-6. DOI:10.1111/bjd.21792</mixed-citation></ref></ref-list></back></article>
